Endocrine Abstracts

Introduction: Acromegaly – a serious debilitating disease resulting in decreased quality and length of life. Due to the late nature of the diagnosis, the lack of prospects for a surgical or non-radical adenomectomy leads to a somatostatin analogues (SA) treatment as primary or secondary therapy, which is a long-term, sometimes lifelong. Therefore, the question of tolerability and prevention of life-threatening complications for these patients is very important. Since the ...

The control of acromegaly with drug therapy (DT) by fg-SRLs is achieved only in 40–50% of cases, due to the heterogeneous composition of somatotrophic tumors. In order to optimize DT stratification of clinical and immunophenotypic biomarkers which make it possible to predict the long-term effectiveness of fg-SRLs at early stages is required. The aim of the work was to assess the informativeness of pharmacotherapeutic testing (% of decrease of IGF-1 level after 3 and 6 mon...

Acromegaly (A) is associated with the bone overgrowth and soft tissue abnormalities due to anabolic, lipolytic and sodium retaining actions of GH.Aim: To investigate the effects of medical treatment on bone mineral density (BMD) of proximal femur, lumbar spine and tissue distribution. We observed 56 patients (14 M and 42 F) with A. BMD was measured using dual-energy X-ray absorptiometry with ‘total body’ program. The patients were treated with ...

Objective: To evaluate the health-related quality of life (HRQoL) in children and adolescents with constitutional tall stature (CTS).Materials and methods: Sixty-two patients (20 males and 42 females) with CTS aged 9.3–16.4 years (12.9±2.4 years, mean±S.D.) were enrolled in this study. Sixty-eight normal subjects (24 males and 44 females) aged 9.8–16.2 years (13.1±2.1 years) served as controls. The evaluation of th...

The efficiency of the prolonged medical therapy of acromegaly with the somatostatin analogues (SA) strictly correlates with the initial sensitivity to the drug. Before the onset of SA therapy 114 patients with acromegaly (35 men and 79 women) aged 54 (48/61) years old (Me (25/75%) underwent the test with Octreotide (Sandostatin®): 300 μg sc within 3 days. The decrease of IGF1 level positively correlated with the age of the acromegaly onset (r=0.38) and negativ...

Objective: To evaluate the pituitary hormone axes in adolescents with constitutional tall stature (CTS).Materials and methods: About 120 patients (54 males and 66 females) with CTS aged 9.6–16.5 years (13.6±2.7 years, mean±S.D.) were enrolled in this study. Sixty-eight normal subjects (24 males and 44 females) aged 9.8–16.2 years (13.1±2.1 years), who were comparable in socioeconomic and nutritional terms, served a...

Diabetes mellitus (DM) is accompanied with a variety of metabolic changes in different systems including bone. In several previous studies it was shown that DM type 1 is associated with a decreased mineral density, whereas the data regarding DM type 2 are still controversial.In the present study we examined the risk of different bone fractures in diabetic patients visiting local trauma clinic during one year (total area population 50.500). The incidence ...

Objective: To report a case of Cushing’s syndrome due to ectopic ACTH secretion and to evaluate role of somatostatin analogues for the localization and postoperative treatment of adrenocorticotropin-secreting bronchial carcinoid tumor.Methods: We describe the clinical presentation of our case and discuss its management.Results: A 57-year-old woman presented with symptoms and physical findings strongly suggestive of Cushing syn...

Introduction: A growth hormone-secreting pituitary adenoma (GH-PA) increases the risk of complications and death. It’s management is determined by MRI data and decrease of insulin-like growth factor-1 (IGF-1) during the octreotide suppression test (OST). Currently, there is evidence that MRI-T2-hypointensive somatotropinoma and high expression of somatostatin receptors type 2 (SSTR2) according to immunohistochemical analysis (IHC) predict high efficacy of somatostatin ana...

Introduction: The PAOLA study in patients with inadequately-controlled acromegaly (n=198) demonstrated superior efficacy of pasireotide long-acting release (LAR; 40 mg/60 mg) in biochemical control (GH <2.5 μg/l and normalized IGF-1) vs continued treatment with octreotide LAR 30 mg/lanreotide Autogel 120 mg (15.4% and 20.0% vs 0%). Here we report preliminary data from the extension phase of PAOLA at wk28.Methods: Pasireotide-LAR (40 mg/...